Control resulted in 14.4 months PFS or 20% better than anticipated
T-Dox arm resulted in about 16 month PFS or about 10-12% improvement over control arm
Issue is focused, no pun intended, on Distant Mets where T-Dox was not as effective.
Now question is what constitutes Distant Mets and can T-Dox support an argument that posiible multiple treatments on new distant mets effectively extent OS significantly. Or does T-Dox do a better job of ablating the primary cancer sight.
Also, the market might consider that HCC is one tough condition. Will futher mining the data demonstrate that the platform has a benifit that can be applied to other cancers. Lots of questions but only one single answer on the Heat Trial right now.